Array Biopharma, Inc. (ARRY) Reports Q2 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.34 -6.18%
Revenue Growth %: -18.0%
Financial Fact:
Net loss: -28.61M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Revenue Growth %: -18.0%
Financial Fact:
Net loss: -28.61M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at Guggenheim
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
- Forum Energy Technologies (FET) Tops Q3 EPS by 29c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
